02/19/2026
We are very proud to spotlight Dr. Gustavo Alves and his continued work advancing saliva-based biomarkers for Alzheimer’s disease.
Dr. Alves recently shared an interview highlighting his research focused on Alzheimer’s diagnosis through saliva—work developed with the Faculty of Medicine at the University of São Paulo (USP), Ribeirão Preto (Brazil).
Why this matters: moving biomarkers toward simpler, more scalable, non-invasive sampling has the potential to accelerate research, enable more repeat/longitudinal monitoring, and broaden access to studies across diverse settings. Saliva won’t replace every modality—but it can be an important part of the toolkit as the field pushes for earlier detection and better monitoring.
What I especially appreciate is that Dr. Alves is also an active contributor in the Saliva Working Group for Alzheimer’s Disease Biomarkers that I co-chair—exactly the kind of global, collaborative momentum this field needs: shared learning, rigorous methods, and strong science.
👏 Congratulations, Dr. Gustavo—excited to see what’s next and grateful for your continued contributions to the community.
Check Dr. Gustavo's post: https://www.linkedin.com/posts/gustavo-alves-santos_alzheimer-saliva-biomarkers-activity-7428935043026358272-5kPM